Immunocytokines
- 8 December 1998
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 80 (3), 277-292
- https://doi.org/10.1016/s0163-7258(98)00033-3
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastomaCancer, 1997
- Clinical strategies for the treatment of neuroblastomaEuropean Journal Of Cancer, 1995
- Antigen-Presenting Cells: Professionals and amateursCurrent Biology, 1995
- Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patientsCancer Immunology, Immunotherapy, 1995
- A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastomaEuropean Journal Of Cancer, 1995
- Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cellsCancer Immunology, Immunotherapy, 1993
- Interleukin-2 in cancer treatment: Disappointing or (still) promising? A reviewCancer Immunology, Immunotherapy, 1993
- A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2aCancer Immunology, Immunotherapy, 1992
- Modulation of T-cell function by gliomasImmunology Today, 1991
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988